We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 34.00 | 33.90 | 34.00 | 34.15 | 33.60 | 34.15 | 2,347,213 | 16:28:56 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 200.00 | 183.65M |
TIDMAPH
RNS Number : 8331S
Alliance Pharma PLC
13 July 2015
Hot Features
Premium
13 July 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Pre-Close Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces its pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2015.
The Group continues to perform well and in line with management's expectations, with sales of approximately GBP22.8m (H1 2014: GBP21.4m) in the first half of the year.
Our growth products continue to deliver, with Hydromol(TM) generating sales of GBP3.3m in the period, 10% higher than in the same period in the prior year despite the additional PPRS rebate deduction.
MacuShield(TM), acquired in February this year, is performing in line with expectations and we look forward to the return of ImmuCyst in the second half of the year, although volumes remain uncertain as Sanofi's facility ramps up production.
Alliance continues to explore a number of acquisition opportunities and remains confident of the outlook for the full year.
The Company's interim results for the six months ended 30 June 2015 are scheduled to be released on 9 September 2015.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Buchanan + 44 (0) 20 7466 5000 Mark Court / Sophie Cowles / Jane Glover Numis Securities Limited + 44 (0) 20 7260 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSFUSIDFISELW
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
